Consortium tackles the challenge of scaling CGT manufacturing
Cellular Origins, the Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have formed a consortium to deliver a fully automated, scalable cell therapy manufacturing platform.
The consortium has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency.
The consortium partners have chosen to collaborate by combining their respective expertise in robotic and digital technologies, manufacturing processes, operations and facilities management, therapy development, novel product processes, and patient delivery.
Providing additional support to the project are ScaleReady with its G-Rex bioreactor platform, and Autolomous with its AutoloMATE eBMR solution.
“Despite the incredible therapeutic performance of cell therapies, therapy development has greatly outpaced the ability for these treatments to be manufactured in sufficient quantities to reach all eligible patients. Manual manufacturing has only been able to be scaled up to deliver a few thousand patient doses per year. The CGT sector is currently only capable of manufacturing sufficient doses to treat less than 7% of eligible patients globally,” said Edwin Stone, CEO, Cellular Origins.
“To deliver therapies to the patients that need them requires fully automated manufacturing of the type that has revolutionised other high-tech manufacturing. This requires solving the cell therapy specific technology challenges that allow the adoption of advanced robotics and AI into cell therapy manufacturing.”
Robotics, AI and automation
The project aims to deliver full integration of the hardware and software of Constellation, Cellular Origins’ CGT robotic manufacturing platform, at the CGT Catapult’s Digital and Automation Testbeds in the Stevenage Manufacturing Innovation Centre, UK.
These Testbeds serve as good manufacturing practice (GMP)-mirroring sandbox environments for de-risked and accelerated testing and adoption of next-generation technologies.
Matthew Durdy, Chief Executive, CGT Catapult, commented: “One of the most challenging problems to international delivery of these therapies to patients continues to be manufacturing. It is clear that robotics, AI and digitisation have now advanced to provide the required solution.”
Resolution will provide key corporate, clinical and commercial expertise as a developer of a new type of cell therapy called Regenerative Macrophage Therapy (RMT).
This will result in the route map and the transformation from manual clinical-scale manufacturing to fully automated, GMP-ready, commercial-scale CGT manufacturing at the scale required to meet areas of significant unmet need.
Dr Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: “Our regenerative macrophage therapy programme is now in the clinic. Our lead asset, RTX001, is currently in Phase I/II studies for the treatment of end-stage liver disease, with additional programmes in development for a number of inflammatory and fibrotic diseases, including graft-versus-host disease and lung fibrosis. This partnership will enable the scalable and cost-efficient manufacturing of next-generation CGTs, ensuring greater patient access to our therapies.”
Diana Turner, Senior Digital Content Editor, DDW
